Mo1255 INCIDENCE AND RISK FACTORS FOR BARRETT'S ESOPHAGUS AFTER SLEEVE GASTRECTOMY: A LARGE POPULATION DATABASE STUDY

Gastro-esophageal reflux disease (GERD) and Barrett’s esophagus are risk factors for esophageal adenocarcinoma (EAC). Chemoprevention is an attractive strategy, more effective than identifying early disease. Since acid reflux can lead to increased cell proliferation, decreased apoptosis, production of reactive oxygen species, DNA damage, and esophageal production of proinflammatory and pro-proliferative cytokines, proton pump inhibitors (PPIs) alone, or in combination with COX-inhibition, are the most suitable chemopreventive agents. Other compounds (statins, metformin, and selected nutraceuticals) cannot currently be recommended. Data are strong enough to warrant PPI treatment of virtually all patients with Barrett’s esophagus, although the best regimen has not yet been defined.

Download Full-text

Prevalence and risk factors of Barrett's esophagus in patients undergoing endoscopy for upper gastrointestinal symptoms

Journal of Digestive Diseases ◽

10.1111/j.1751-2980.2010.00419.x ◽

2010 ◽

Vol 11 (2) ◽

pp. 83-87 ◽

Cited By ~ 28

Author(s):

Li Shou XIONG ◽

Yi CUI ◽

Jin Ping WANG ◽

Jin Hui WANG ◽

Ling XUE ◽

...

Keyword(s):

Risk Factors ◽

Barrett’S Esophagus ◽

Barrett's Esophagus ◽

Gastrointestinal Symptoms ◽

Upper Gastrointestinal Symptoms ◽

Upper Gastrointestinal

Download Full-text

Correlation Between Traditional Barrett's Esophagus Risk Factors and Gastroesophageal Acid Reflux and Esophageal Mucosal Injury

SSRN Electronic Journal ◽

10.2139/ssrn.3756792 ◽

2020 ◽

Author(s):

Christopher Toivonen ◽

Sirish Rao ◽

Yazan Addasi ◽

Ryan W. Walters ◽

Kalyana Nandipati ◽

...

Keyword(s):

Risk Factors ◽

Barrett’S Esophagus ◽

Barrett's Esophagus ◽

Mucosal Injury ◽

Acid Reflux

Download Full-text

Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort

Diseases of the Esophagus ◽

10.1093/dote/doz061 ◽

2019 ◽

Cited By ~ 2

Author(s):

K Y Song ◽

A J Henn ◽

A A Gravely ◽

H Mesa ◽

S Sultan ◽

...

Keyword(s):

Risk Factors ◽

Risk Factor ◽

Barrett’S Esophagus ◽

Barrett's Esophagus ◽

Independent Risk Factor ◽

High Grade Dysplasia ◽

Low Grade ◽

High Grade ◽

Increased Risk ◽

Low Grade Dysplasia

SUMMARY Patients with Barrett's esophagus (BE) and low-grade dysplasia (LGD) are at increased risk of esophageal adenocarcinoma (EAC), although many regress to nondysplastic BE. This has significant clinical importance for patients being considered for endoscopic eradication therapy. Our aim is to determine the risk for progression in patients with confirmed persistent LGD. We performed a single-center retrospective cohort study of patients with BE and confirmed LGD between 2006 and 2016. Confirmed LGD was defined as LGD diagnosed by consensus conference with an expert GI pathologist or review by an expert GI pathologist and persistence as LGD present on subsequent endoscopic biopsy. The primary outcome was the incidence rate of HGD (high-grade dysplasia)/EAC. Secondary outcomes included risk factors for dysplastic progression. Risk factors for progression were assessed using univariate and multivariate analysis with logistic regression. Of 69 patients (mean age 65.2 years) with confirmed LGD were included. In total, 16 of 69 patients (23.2%) with LGD developed HGD/EAC during a median follow-up of 3.74 years (IQR, 1.24–5.45). For persistent confirmed LGD, the rate was 6.44 (95% confidence interval (CI), 2.61–13.40) compared to 2.61 cases per 100 patient-years (95% CI, 0.83–6.30) for nonpersistent LGD. Persistent LGD was found in only 29% of patients. Persistent LGD was an independent risk factor for the development of HGD/EAC (OR 4.18; [95% CI, 1.03–17.1]). Persistent confirmed LGD, present in only 1/3 of patients, was an independent risk factor for the development of HGD/EAC. Persistence LGD may be useful in decision making regarding the management of BE.

Download Full-text